Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Probiotics
  4. Fast Track Articles
  5. Fast Track Article
image of Probiotics in Mitigating Adverse Effects of Intestinal Resection and Chemotherapy: A Meta-analysis

Abstract

Introduction

Colorectal cancer (CRC) imposes a significant burden on global healthcare systems, particularly in Europe, where it ranks among the most diagnosed cancers and leading causes of cancer-related deaths. With an estimated 50,000 deaths attributed to CRC in 2023 alone, a pressing need for innovative approaches to prevention, early detection, and treatment is evident. While chemotherapy and surgical resection remain crucial therapeutic strategies, they often entail significant adverse effects, such as chemotherapy-induced diarrhea and post-surgical complications.

Method

Recent research underscores the role of the microbiota in modulating these side effects, with dysbiosis associated with increased risks. Probiotics, known for their ability to restore microbial balance, have emerged as a promising adjunctive therapy for mitigating treatment-related complications in CRC patients. However, the efficacy of probiotics remains debated, necessitating a meta-analysis to provide a comprehensive assessment. Hence, this study aimed to evaluate the efficacy of probiotics in reducing complications in CRC patients undergoing chemotherapy and intestinal surgery. For this purpose, thirteen randomized controlled trials (RCTs) meeting strict inclusion criteria were included in the meta-analysis.

Result

Probiotic administration was associated with significant reductions in postoperative infections, including surgical site infections (SSI), pneumonia, urinary tract infections (UTI), and central line infections, showing a Risk Ratio (RR) of 0.74 with a Confidence Interval (CI) of 95%. Moreover, probiotics demonstrated efficacy in mitigating chemotherapy-induced diarrhea and post-surgical complications, such as anastomosis loosening and abdominal disorders, with an RR of 0.35 and 0.74, respectively, with a CI of 95%. While promising, further research is needed to optimize probiotic interventions and address potential interactions with concurrent therapies. Integrating probiotics into perioperative care protocols presents a convincing opportunity to enhance surgical outcomes and improve patient prognosis following CRC resection.

Conclusion

Future randomized controlled trials should focus on identifying optimal probiotic strains, dosages, and administration timing to maximize therapeutic benefits.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/probiot/10.2174/0126666499314634241028103336
2024-12-11
2025-01-17

  • From This Site

    /content/journals/probiot/10.2174/0126666499314634241028103336
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Xi Y. Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021 14 10 101174 10.1016/j.tranon.2021.101174 34243011
    [Google Scholar]
  2. Sawicki T. Ruszkowska M. Danielewicz A. Niedźwiedzka E. Arłukowicz T. Przybyłowicz K.E. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers 2021 13 9 2025 10.3390/cancers13092025 33922197
    [Google Scholar]
  3. Siegel R.L. Wagle N.S. Cercek A. Smith R.A. Jemal A. Colorectal cancer statistics CA Cancer J. Clin. 2023 73 3 233 254 10.3322/caac.21772 36856579
    [Google Scholar]
  4. Rentsch M. Schiergens T. Khandoga A. Werner J. Surgery for colorectal cancer - trends, developments, and future perspectives. Visc. Med. 2016 32 3 184 191 10.1159/000446490 27493946
    [Google Scholar]
  5. Arredondo J. Martínez P. Baixauli J. Pastor C. Rodríguez J. Pardo F. Rotellar F. Chopitea A. Hernández-Lizoáin J.L. Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer. J. Gastrointest. Oncol. 2014 5 2 148 153 24772343
    [Google Scholar]
  6. Damato A. Ghidini M. Dottorini L. Tomasello G. Iaculli A. Ghidini A. Luciani A. Petrelli F. Chemotherapy duration for various indications in colorectal cancer: A Review. Curr. Oncol. Rep. 2023 25 4 341 352 10.1007/s11912‑023‑01378‑5 36781622
    [Google Scholar]
  7. Stein A. Voigt W. Jordan K. Review: Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2010 2 1 51 63 10.1177/1758834009355164 21789126
    [Google Scholar]
  8. Benedek Z. Coroș M.F. The impact of sarcopenia on the postoperative outcome in colorectal cancer surgery. Med. Pharm. Rep. 2023 96 1 20 27 10.15386/mpr‑2483 36818326
    [Google Scholar]
  9. Tsalikidis C. Mitsala A. Mentonis V.I. Romanidis K. Pappas-Gogos G. Tsaroucha A.K. Pitiakoudis M. Predictive factors for anastomotic leakage following colorectal cancer surgery: Where are we and where are we going? Curr. Oncol. 2023 30 3 3111 3137 10.3390/curroncol30030236 36975449
    [Google Scholar]
  10. Rebersek M. Gut microbiome and its role in colorectal cancer. BMC Cancer 2021 21 1 1325 10.1186/s12885‑021‑09054‑2 34895176
    [Google Scholar]
  11. Quaglio A.E.V. Grillo T.G. Oliveira E.C.S.D. Stasi L.C.D. Sassaki L.Y. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J. Gastroenterol. 2022 28 30 4053 4060 10.3748/wjg.v28.i30.4053 36157114
    [Google Scholar]
  12. Wong S.H. Yu J. Gut microbiota in colorectal cancer: Mechanisms of action and clinical applications. Nat. Rev. Gastroenterol. Hepatol. 2019 16 11 690 704 10.1038/s41575‑019‑0209‑8 31554963
    [Google Scholar]
  13. Fei Z. Lijuan Y. Xi Y. Wei W. Jing Z. Miao D. Shuwen H. Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer. Gut Pathog. 2019 11 1 18 10.1186/s13099‑019‑0299‑4 31168325
    [Google Scholar]
  14. Kawasaki Y. Kakimoto K. Tanaka Y. Shimizu H. Nishida K. Numa K. Kinoshita N. Tatsumi Y. Nakazawa K. Koshiba R. Hirata Y. Ota K. Sakiyama N. Terazawa T. Takeuchi T. Miyazaki T. Goto M. Yokota H. Makizaki Y. Tanaka Y. Nakajima S. Ohno H. Higuchi K. Nakamura S. Nishikawa H. Relationship between chemotherapy-induced diarrhea and intestinal microbiome composition. Digestion 2023 104 5 357 369 10.1159/000528282 37231829
    [Google Scholar]
  15. Wei L. Wen X.S. Xian C.J. Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating toll-like receptor signaling pathways. Int. J. Mol. Sci. 2021 22 17 9474 10.3390/ijms22179474 34502383
    [Google Scholar]
  16. Shi Y. Cui H. Wang F. Zhang Y. Xu Q. Liu D. Wang K. Hou S. Role of gut microbiota in postoperative complications and prognosis of gastrointestinal surgery: A narrative review. Medicine (Baltimore) 2022 101 29 e29826 10.1097/MD.0000000000029826 35866808
    [Google Scholar]
  17. Stivala A. Carota G. Fuochi V. Furneri P.M. Lactobacillus rhamnosus AD3 as a promising alternative for probiotic products. Biomolecules 2021 11 1 94 10.3390/biom11010094 33450875
    [Google Scholar]
  18. Maldonado Galdeano C. Cazorla S.I. Lemme Dumit J.M. Vélez E. Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann. Nutr. Metab. 2019 74 2 115 124 10.1159/000496426 30673668
    [Google Scholar]
  19. Liu Y. Wang J. Wu C. Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front. Nutr. 2022 8 634897 10.3389/fnut.2021.634897 35047537
    [Google Scholar]
  20. Wang X. Zhang P. Zhang X. Probiotics regulate gut microbiota: An effective method to improve immunity. Molecules 2021 26 19 6076 10.3390/molecules26196076 34641619
    [Google Scholar]
  21. Zhang J.W. Du P. Yang B-R. Gao J. Fang W.J. Ying C.M. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am. J. Med. Sci. 2012 343 3 199 205 10.1097/MAJ.0b013e31823aace6 22197980
    [Google Scholar]
  22. Bajramagic S. Hodzic E. Mulabdic A. Holjan S. Smajlovic S. Rovcanin A. Usage of probiotics and its clinical significance at surgically treated patients sufferig from colorectal carcinoma. Med. Arh. 2019 73 5 316 320 10.5455/medarh.2019.73.316‑320 31819304
    [Google Scholar]
  23. Delia P. Sansotta G. Donato V. Frosina P. Messina G. De Renzis C. Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 2007 13 6 912 915 10.3748/wjg.v13.i6.912 17352022
    [Google Scholar]
  24. Flesch A.T. Tonial S.T. Contu P.D.C. Damin D.C. Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: A randomized, double-blind clinical trial. Rev. Col. Bras. Cir. 2017 44 6 567 573 10.1590/0100‑69912017006004 29267553
    [Google Scholar]
  25. Polakowski C.B. Kato M. Preti V.B. Schieferdecker M.E.M. Ligocki Campos A.C. Impact of the preoperative use of synbiotics in colorectal cancer patients: A prospective, randomized, double-blind, placebo-controlled study. Nutrition 2019 58 40 46 10.1016/j.nut.2018.06.004 30278428
    [Google Scholar]
  26. Kotzampassi K. Stavrou G. Damoraki G. Georgitsi M. Basdanis G. Tsaousi G. Giamarellos-Bourboulis E.J. A Four‐probiotics regimen reduces postoperative complications after colorectal surgery: A randomized, double‐blind, placebo‐controlled study. World J. Surg. 2015 39 11 2776 2783 10.1007/s00268‑015‑3071‑z 25894405
    [Google Scholar]
  27. Mego M. Chovanec J. Vochyanova-Andrezalova I. Konkolovsky P. Mikulova M. Reckova M. Miskovska V. Bystricky B. Beniak J. Medvecova L. Lagin A. Svetlovska D. Spanik S. Zajac V. Mardiak J. Drgona L. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement. Ther. Med. 2015 23 3 356 362 10.1016/j.ctim.2015.03.008 26051570
    [Google Scholar]
  28. Österlund P. Ruotsalainen T. Korpela R. Saxelin M. Ollus A. Valta P. Kouri M. Elomaa I. Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br. J. Cancer 2007 97 8 1028 1034 10.1038/sj.bjc.6603990 17895895
    [Google Scholar]
  29. Sadahiro S. Suzuki T. Tanaka A. Okada K. Kamata H. Ozaki T. Koga Y. Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: Prospective randomized trial. Surgery 2014 155 3 493 503 10.1016/j.surg.2013.06.002 24524389
    [Google Scholar]
  30. Tan C.K. Said S. Rajandram R. Wang Z. Roslani A.C. Chin K.F. Pre‐surgical administration of microbial cell preparation in colorectal cancer patients: A randomized controlled trial. World J. Surg. 2016 40 8 1985 1992 10.1007/s00268‑016‑3499‑9 27098538
    [Google Scholar]
  31. Golkhalkhali B. Rajandram R. Paliany A.S. Ho G.F. Wan Ishak W.Z. Johari C.S. Chin K.F. Strain‐specific probiotic (microbial cell preparation) and omega‐3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: A randomized controlled trial. Asia Pac. J. Clin. Oncol. 2018 14 3 179 191 10.1111/ajco.12758 28857425
    [Google Scholar]
  32. Zaharuddin L. Mokhtar N.M. Muhammad Nawawi K.N. Raja Ali R.A. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019 19 1 131 10.1186/s12876‑019‑1047‑4 31340751
    [Google Scholar]
  33. Gianotti L. Morelli L. Galbiati F. Rocchetti S. Coppola S. Beneduce A. Gilardini C. Zonenschain D. Nespoli A. Braga M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J. Gastroenterol. 2010 16 2 167 175 10.3748/wjg.v16.i2.167 20066735
    [Google Scholar]
  34. Ishikawa H. Akedo I. Otani T. Suzuki T. Nakamura T. Takeyama I. Ishiguro S. Miyaoka E. Sobue T. Kakizoe T. Randomized trial of dietary fiber andLactobacillus casei administration for prevention of colorectal tumors. Int. J. Cancer 2005 116 5 762 767 10.1002/ijc.21115 15828052
    [Google Scholar]
  35. Huang F. Li S. Chen W. Han Y. Yao Y. Yang L. Li Q. Xiao Q. Wei J. Liu Z. Chen T. Deng X. Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients. Nutrients 2023 15 2 356 10.3390/nu15020356 36678227
    [Google Scholar]
  36. Liu Z. Qin H. Yang Z. Xia Y. Liu W. Yang J. Jiang Y. Zhang H. Yang Z. Wang Y. Zheng Q. Randomised clinical trial: The effects of perioperative probiotic treatment on barrier function and post‐operative infectious complications in colorectal cancer surgery – a double‐blind study. Aliment. Pharmacol. Ther. 2011 33 1 50 63 10.1111/j.1365‑2036.2010.04492.x 21083585
    [Google Scholar]
  37. Liu Z. Li C. Huang M. Tong C. Zhang X. Wang L. Peng H. Lan P. Zhang P. Huang N. Peng J. Wu X. Luo Y. Qin H. Kang L. Wang J. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: A double-center and double-blind randomized clinical trial. BMC Gastroenterol. 2015 15 1 34 10.1186/s12876‑015‑0260‑z 25881090
    [Google Scholar]
  38. Niu W. Li Z. Li Z. Hu X. Wang X. Ding Y. Li C. Yu B. A prospective and randomized control study on effects of thymalfasin for injection on perioperative immune function and long-term prognosis of patients with colorectal cancer. Biotechnol. Genet. Eng. Rev. 2023 1 13 10.1080/02648725.2023.2216972 37248723
    [Google Scholar]
  39. Pak H. Maghsoudi L.H. Soltanian A. Gholami F. Surgical complications in colorectal cancer patients. Ann. Med. Surg. (Lond.) 2020 55 13 18 10.1016/j.amsu.2020.04.024 32435475
    [Google Scholar]
  40. Hernandez Dominguez O. Yilmaz S. Steele S.R. Stage I.V. Stage IV colorectal cancer management and treatment. J. Clin. Med. 2023 12 5 2072 10.3390/jcm12052072 36902858
    [Google Scholar]
  41. Altintas M.M. Kaya S. Kocaoglu A.E. Mulkut F. Does preoperative anaemia have an effect on the perioperative period in colorectal cancer surgery? Niger. J. Clin. Pract. 2022 25 7 1102 1106 10.4103/njcp.njcp_1664_21 35859472
    [Google Scholar]
  42. Gheybi K. Buckley E. Vitry A. Roder D. Occurrence of comorbidity with colorectal cancer and variations by age and stage at diagnosis. Cancer Epidemiol. 2022 80 102246 10.1016/j.canep.2022.102246 36067574
    [Google Scholar]
  43. Koliarakis I. Athanasakis E. Sgantzos M. Mariolis-Sapsakos T. Xynos E. Chrysos E. Souglakos J. Tsiaoussis J. Intestinal microbiota in colorectal cancer surgery. Cancers 2020 12 10 3011 10.3390/cancers12103011 33081401
    [Google Scholar]
  44. Han C. Chen W. Ye X.L. Cheng F. Wang X.Y. Liu A.B. Mu Z.H. Jin X.J. Weng Y.H. Risk factors analysis of surgical site infections in postoperative colorectal cancer: A nine-year retrospective study. BMC Surg. 2023 23 1 320 10.1186/s12893‑023‑02231‑z 37872509
    [Google Scholar]
  45. Antonic V. Stojadinovic A. Kester K.E. Weina P.J. Brücher B.L.D.M. Protic M. Avital I. Izadjoo M. Significance of infectious agents in colorectal cancer development. J. Cancer 2013 4 3 227 240 10.7150/jca.5835 23459622
    [Google Scholar]
  46. Huang W.K. Chang J.W.C. See L.C. Tu H.T. Chen J.S. Liaw C.C. Lin Y.C. Yang T.S. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: An 11‐year follow‐up study. Colorectal Dis. 2012 14 12 e794 e801 10.1111/j.1463‑1318.2012.03174.x 22776247
    [Google Scholar]
  47. Regenbogen S.E. Read T.E. Roberts P.L. Marcello P.W. Schoetz D.J. Ricciardi R. Urinary tract infection after colon and rectal resections: More common than predicted by risk-adjustment models. J. Am. Coll. Surg. 2011 213 6 784 792 10.1016/j.jamcollsurg.2011.08.013 21945417
    [Google Scholar]
  48. Anthony T. Murray B.W. Sum-Ping J.T. Lenkovsky F. Vornik V.D. Parker B.J. McFarlin J.E. Hartless K. Huerta S. Evaluating an evidence-based bundle for preventing surgical site infection: A randomized trial. Arch. Surg. 2011 146 3 263 269 10.1001/archsurg.2010.249 21079110
    [Google Scholar]
  49. Dhole S. Mahakalkar C. Kshirsagar S. Bhargava A. Antibiotic prophylaxis in surgery: Current insights and future directions for surgical site infection prevention. Cureus 2023 15 10 e47858 10.7759/cureus.47858 38021553
    [Google Scholar]
  50. Shah T. Baloch Z. Shah Z. Cui X. Xia X. The intestinal microbiota: Impacts of antibiotics therapy, colonization resistance, and diseases. Int. J. Mol. Sci. 2021 22 12 6597 10.3390/ijms22126597 34202945
    [Google Scholar]
  51. Probiotics in food : Health and nutritional properties and guidelines for evaluation. FAO Food Nutr Pap. 2006 85 56
    [Google Scholar]
  52. Hill C. Guarner F. Reid G. Gibson G.R. Merenstein D.J. Pot B. Morelli L. Canani R.B. Flint H.J. Salminen S. Calder P.C. Sanders M.E. The International Scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014 11 8 506 514 10.1038/nrgastro.2014.66 24912386
    [Google Scholar]
  53. Saha U.B. Saroj S.D. Lactic acid bacteria: Prominent player in the fight against human pathogens. Expert Rev. Anti Infect. Ther. 2022 20 11 1435 1453 10.1080/14787210.2022.2128765 36154442
    [Google Scholar]
  54. Bersch K.L. DeMeester K.E. Zagani R. Chen S. Wodzanowski K.A. Liu S. Mashayekh S. Reinecker H.C. Grimes C.L. Bacterial peptidoglycan fragments differentially regulate innate immune signaling. ACS Cent. Sci. 2021 7 4 688 696 10.1021/acscentsci.1c00200 34056099
    [Google Scholar]
  55. Piccioni A. Cicchinelli S. Valletta F. De Luca G. Longhitano Y. Candelli M. Ojetti V. Sardeo F. Navarra S. Covino M. Franceschi F. Gut microbiota and autoimmune diseases: A charming real world together with probiotics. Curr. Med. Chem. 2022 29 18 3147 3159 10.2174/0929867328666210922161913 34551690
    [Google Scholar]
  56. Gershuni V.M. Friedman E.S. The microbiome-host interaction as a potential driver of anastomotic leak. Curr. Gastroenterol. Rep. 2019 21 1 4 10.1007/s11894‑019‑0668‑7 30684121
    [Google Scholar]
  57. Tzikos G. Tsalkatidou D. Stavrou G. Thoma G. Chorti A. Tsilika M. Michalopoulos A. Papavramidis T. Giamarellos-Bourboulis E.J. Kotzampassi K. A four-probiotic regime to reduce surgical site infections in multi-trauma patients. Nutrients 2022 14 13 2620 10.3390/nu14132620 35807801
    [Google Scholar]
  58. Abdulah D.M. Sulaiman S.J. Ahmed Z.W. Effect of probiotics plus zinc supplementation on clinical outcomes of infants and children with acute infectious diarrhea: A randomized controlled trial. Clin. Exp. Pediatr. 2024 67 4 203 212 10.3345/cep.2023.01340 38374706
    [Google Scholar]
  59. Merenstein D Tan T Herbin Smith K. Exploratory pilot studies to demonstrate mechanisms of preventing antibiotic-associated diarrhea and the role for probiotics. Ann Fam Med. 2024 21 3
    [Google Scholar]
  60. Sausa M. Fucarino A. Paladino L. Zummo F.P. Fabbrizio A. Di Felice V. Rappa F. Barone R. Marino Gammazza A. Macaluso F. Probiotics as potential therapeutic agents: Safeguarding skeletal muscle against alcohol-induced damage through the gut–liver–muscle axis. Biomedicines 2024 12 2 382 10.3390/biomedicines12020382 38397983
    [Google Scholar]
  61. Banoth D. Wali M.H. Bekova K. Abdulla N. Gurugubelli S. Lin Y.M. Khan S. The role of oral probiotics in alleviating inflammation, symptom relief, and postoperative recurrence and their side effects in adults with Crohn’s disease: A systematic review. Cureus 2023 15 12 e50901 10.7759/cureus.50901 38259373
    [Google Scholar]
  62. Fuochi V. Spampinato M. Distefano A. Palmigiano A. Garozzo D. Zagni C. Rescifina A. Li Volti G. Furneri P.M. Soluble peptidoglycan fragments produced by Limosilactobacillus fermentum with antiproliferative activity are suitable for potential therapeutic development: A preliminary report. Front. Mol. Biosci. 2023 10 1082526 10.3389/fmolb.2023.1082526 36876040
    [Google Scholar]
  63. Saffar K.N. Larypoor M. Torbati M.B. Analyzing of colorectal cancerrelated genes and microRNAs expression profiles in response to probiotics Lactobacillus acidophilus and Saccharomyces cerevisiae in colon cancer cell lines. Mol. Biol. Rep. 2024 51 1 122 10.1007/s11033‑023‑09008‑w 38227272
    [Google Scholar]
  64. Budu O. Mioc A. Soica C. Caruntu F. Milan A. Oprean C. Lighezan D. Rotunjanu S. Ivan V. Banciu C. Lactiplantibacillus plantarum induces apoptosis in melanoma and breast cancer cells. Microorganisms 2024 12 1 182 10.3390/microorganisms12010182 38258008
    [Google Scholar]
  65. Ruiz-Sánchez C. Escudero-López B. Fernández-Pachón M.S. Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome. Endocrinol. Diabetes Nutr. (Engl. Ed.) 2024 71 1 19 30 10.1016/j.endien.2024.01.003 38331656
    [Google Scholar]
  66. Ang X.Y. Roslan N.S. Ahmad N. Yusof S.M. Abdullah N. Nik Ab Rahman N.N. Woon J.J. Teh C.S.J. Todorov S.D. Liu G. Liong M.T. Lactobacillus probiotics restore vaginal and gut microbiota of pregnant women with vaginal candidiasis. Benef. Microbes 2023 14 5 421 431 10.1163/18762891‑20220103 38350486
    [Google Scholar]
  67. Fuochi V. Volti G. Furneri P. Probiotic Properties of Lactobacillus fermentum strains isolated from human oral samples and description of their antibacterial activity. Curr. Pharm. Biotechnol. 2017 18 2 138 149 10.2174/1389201017666161229153530 28034294
    [Google Scholar]
  68. Gan L. Wang Y. Huang S. Zheng L. Feng Q. Liu H. Liu P. Zhang K. Chen T. Fang N. Therapeutic evaluation of Bifidobacterium animalis subsp. lactis MH-02 as an adjunctive treatment in patients with reflux esophagitis: A randomized, double-blind, placebo-controlled trial. Nutrients 2024 16 3 342 10.3390/nu16030342 38337627
    [Google Scholar]
  69. Zhang Q. Li G. Zhao W. Wang X. He J. Zhou L. Zhang X. An P. Liu Y. Zhang C. Zhang Y. Liu S. Zhao L. Liu R. Li Y. Jiang W. Wang X. Wang Q. Fang B. Zhao Y. Ren Y. Niu X. Li D. Shi S. Hung W.L. Wang R. Liu X. Ren F. Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: A randomized placebo-controlled clinical trial. Nat. Commun. 2024 15 1 227 10.1038/s41467‑023‑44292‑x 38172093
    [Google Scholar]
  70. Sarlin S. Koskela U. Honkila M. Tähtinen P.A. Pokka T. Renko M. Tapiainen T. Streptococcus salivarius probiotics to prevent acute otitis media in children. JAMA Netw. Open 2023 6 11 e2340608 10.1001/jamanetworkopen.2023.40608 37917062
    [Google Scholar]
  71. Amitay E.L. Carr P.R. Gies A. Laetsch D.C. Brenner H. Probiotic/Synbiotic treatment and postoperative complications in colorectal cancer patients: Systematic review and meta-analysis of randomized controlled trials. Clin. Transl. Gastroenterol. 2020 11 12 e00268 10.14309/ctg.0000000000000268 33512803
    [Google Scholar]
  72. An S. Kim K. Kim M.H. Jung J.H. Kim Y. Perioperative probiotics application for preventing postoperative complications in patients with colorectal cancer: A systematic review and meta-analysis. Medicina (Kaunas) 2022 58 11 1644 10.3390/medicina58111644 36422183
    [Google Scholar]
  73. Chen Y. Qi A. Teng D. Li S. Yan Y. Hu S. Du X. Probiotics and synbiotics for preventing postoperative infectious complications in colorectal cancer patients: A systematic review and meta-analysis. Tech. Coloproctol. 2022 26 6 425 436 10.1007/s10151‑022‑02585‑1 35348943
    [Google Scholar]
  74. Danis R. Mego M. Antonova M. Stepanova R. Svobodnik A. Hejnova R. Wawruch M. Orally administered probiotics in the prevention of chemotherapy (± Radiotherapy)-induced gastrointestinal toxicity: A systematic review with meta-analysis of randomized trials. Integr. Cancer Ther. 2022 21 10.1177/15347354221144309 36567453
    [Google Scholar]
  75. Ouyang X. Li Q. Shi M. Niu D. Song W. Nian Q. Li X. Ding Z. Ai X. Wang J. Probiotics for preventing postoperative infection in colorectal cancer patients: A systematic review and meta-analysis. Int. J. Colorectal Dis. 2019 34 3 459 469 10.1007/s00384‑018‑3214‑4 30539265
    [Google Scholar]
  76. Zeng J. Ji Y. Liang B. Zhang G. Chen D. Zhu M. Wu S. Kuang W. The effect of pro/synbiotics on postoperative infections in colorectal cancer patients: A systematic review and meta-analysis. Complement. Ther. Clin. Pract. 2021 43 101370 10.1016/j.ctcp.2021.101370 33894576
    [Google Scholar]
  77. Kinross J.M. Markar S. Karthikesalingam A. Chow A. Penney N. Silk D. Darzi A. A meta-analysis of probiotic and synbiotic use in elective surgery: Does nutrition modulation of the gut microbiome improve clinical outcome? JPEN J. Parenter. Enteral Nutr. 2013 37 2 243 253 10.1177/0148607112452306 22750803
    [Google Scholar]
  78. Chowdhury A.H. Adiamah A. Kushairi A. Lobo D.N. Response to the comment on “Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery: A systematic review and meta-analysis of randomized controlled trials”. Ann. Surg. 2021 274 6 e676 e677 10.1097/SLA.0000000000003759 31895712
    [Google Scholar]
  79. Chowdhury A.H. Adiamah A. Kushairi A. Varadhan K.K. Krznaric Z. Kulkarni A.D. Neal K.R. Lobo D.N. Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery. Ann. Surg. 2020 271 6 1036 1047 10.1097/SLA.0000000000003581 31469748
    [Google Scholar]
  80. Moreira M.M. Carriço M. Capelas M.L. Pimenta N. Santos T. Ganhão-Arranhado S. Mäkitie A. Ravasco P. The impact of pre-, pro- and synbiotics supplementation in colorectal cancer treatment: A systematic review. Front. Oncol. 2024 14 1395966 10.3389/fonc.2024.1395966 38807764
    [Google Scholar]
  81. Wu X.D. Wu D. Liu Y. Huang W. Comment on “Perioperative probiotics or synbiotics in adults undergoing elective abdominal surgery. Ann. Surg. 2021 274 6 e675 e676 10.1097/SLA.0000000000003762 31895710
    [Google Scholar]
  82. McFarland L.V. Evans C.T. Goldstein E.J.C. Strain-Specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis. Front. Med. (Lausanne) 2018 5 124 10.3389/fmed.2018.00124 29868585
    [Google Scholar]
  83. Min S. Than N. Shin Y.C. Hu G. Shin W. Ambrosini Y.M. Kim H.J. Live probiotic bacteria administered in a pathomimetic Leaky Gut Chip ameliorate impaired epithelial barrier and mucosal inflammation. Sci. Rep. 2022 12 1 22641 10.1038/s41598‑022‑27300‑w 36587177
    [Google Scholar]
  84. Batista V.L. De Jesus L.C.L. Tavares L.M. Barroso F.L.A. Fernandes L.J.S. Freitas A.S. Americo M.F. Drumond M.M. Mancha-Agresti P. Ferreira E. Laguna J.G. Alcantara L.C.J. Azevedo V. Paraprobiotics and postbiotics of Lactobacillus delbrueckii CIDCA 133 Mitigate 5-FU-induced intestinal inflammation. Microorganisms 2022 10 7 1418 10.3390/microorganisms10071418 35889136
    [Google Scholar]
  85. Gao Z. Guo B. Gao R. Zhu Q. Wu W. Qin H. Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Mol. Med. Rep. 2015 12 4 6119 6127 10.3892/mmr.2015.4124 26238090
    [Google Scholar]
  86. Rafter J. Probiotics and colon cancer. Best Pract. Res. Clin. Gastroenterol. 2003 17 5 849 859 10.1016/S1521‑6918(03)00056‑8 14507593
    [Google Scholar]
  87. Rafter J. The effects of probiotics on colon cancer development. Nutr. Res. Rev. 2004 17 2 277 284 10.1079/NRR200484 19079931
    [Google Scholar]
  88. Azcárate-Peril M.A. Sikes M. Bruno-Bárcena J.M. The intestinal microbiota, gastrointestinal environment and colorectal cancer: A putative role for probiotics in prevention of colorectal cancer? Am. J. Physiol. Gastrointest. Liver Physiol. 2011 301 3 G401 G424 10.1152/ajpgi.00110.2011 21700901
    [Google Scholar]
  89. Han M. Wang K. Sun L. Liu W. Dong W. Prevention of ventilator-associated pneumonia with probiotics: An overview of systematic reviews. Front. Microbiol. 2024 15 1345278 10.3389/fmicb.2024.1345278 38426068
    [Google Scholar]
  90. Jirillo E. Palmirotta R. Colella M. Santacroce L. A bird’s-eye view of the pathophysiologic role of the human urobiota in health and disease: Can we modulate it? Pathophysiology 2024 31 1 52 67 10.3390/pathophysiology31010005 38390942
    [Google Scholar]
  91. Salazar A.M. Neugent M.L. De Nisco N.J. Mysorekar I.U. Gut-bladder axis enters the stage: Implication for recurrent urinary tract infections. Cell Host Microbe 2022 30 8 1066 1069 10.1016/j.chom.2022.07.008 35952642
    [Google Scholar]
  92. Yang H.J. Kim D.S. Lee K.W. Kim Y.H. The urinary microbiome; Axis crosstalk and short-chain fatty acid. Diagnostics 2022 12 12 3119 10.3390/diagnostics12123119 36553126
    [Google Scholar]
/content/journals/probiot/10.2174/0126666499314634241028103336
Loading
Probiotics in Mitigating Adverse Effects of Intestinal Resection and Chemotherapy: A Meta-analysis
Bentham Science Publishers ; https://doi.org/10.2174/0126666499314634241028103336
/content/journals/probiot/10.2174/0126666499314634241028103336
/content/journals/probiot/10.2174/0126666499314634241028103336
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: chemotherapy ; probiotics ; bacterial infections ; anastomotic leaks ; intestinal resection ; gut microbiota ; Colorectal cancer (CRC) ; diarrhea

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test